Volume 1.35 | Sep 17

Prostate Cell News 1.35, September 17, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

The Putative Cannabinoid Receptor GPR55 Defines a Novel Autocrine Loop in Cancer Cell Proliferation 
In this study, researchers show that GPR55 is expressed in several prostate and ovarian cancer cell lines, both at the mRNA and at the protein level, and that it has a critical role in regulating proliferation and anchorage-independent growth. [Oncogene]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN HOW STEMCELL Technologies Inc
 



SCIENCE NEWS

Blood Test Accurately Predicts Death from Prostate Cancer up to 25 Years in Advance
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers. [Press release from the Memorial Sloan-Kettering Cancer Center discussing online prepublication in the British Medical Journal]

Sharper Criteria for Early Detection of Prostate Cancer
Some men benefit more from early detection of prostate cancer than others. Researchers have now discovered for which group of men this applies which means that the criteria for screening and early diagnosis can be tightened. [Press release from Erasmus MC discussing online prepublication in Cancer]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies
 
 
WATCH THE VIDEO STEMCELL Technologies Inc
 



LABORATORY RESEARCH

A Critical Role of Integrin-Linked Kinase, ch-TOG and TACC3 in Centrosome Clustering in Cancer Cells
In this study, researchers demonstrate that the integrin-linked kinase, a protein critically involved in actin and mitotic microtubule organization, is required for centrosome clustering. [Oncogene]

Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing ROS-Mediated Cellular Senescence
In the present study, researchers demonstrate that knockdown of the inwardly rectifying K+ channel Kir2.2 induced growth arrest without additional cellular stress in cancer cells lacking functional p53, p16, and/or Rb. Kir2.2 knockdown also induced senescence-associated beta-galactosidase activity and up-regulated senescence marker proteins in multiple cancer cell lines derived from different tissues, including prostate, stomach, and breast. [Mol Cancer Ther]

Secretory Phospholipase A2-IIa is Involved in Prostate Cancer Progression and May Potentially Serve as a Biomarker for Prostate Cancer
Here, researchers found that secretory phospholipase A2-IIa is overexpressed in androgen-independent prostate cancer LNCaP-AI cells relative to their androgen-dependent LNCaP cell counterparts. [Carcinogenesis]

A Dietary Tomato Supplement Prevents Prostate Cancer in TRAMP Mice
Transgenic adenocarcinoma of the mouse prostate (TRAMP) is a model for progressive prostate cancer that mirrors the stages of the human form. In this study, the effects of a diet enriched with processed whole tomatoes on survival, tumorigenesis, and progression of prostate cancer, and the antioxidant and inflammatory status of TRAMP mice were investigated. [Cancer Prev Res]

Comparison of Methyl-DNA Immunoprecipitation (MeDIP) and Methyl-CpG Binding Domain (MBD) Protein Capture for Genome-Wide DNA Methylation Analysis Reveal CpG Sequence Coverage Bias
In this study, researchers compared two commonly used approaches to enrich for methylated DNA regions of the genome, namely methyl-DNA immunoprecipitation that is based on enrichment with antibodies specific for 5′-methylcytosine, and capture of methylated DNA using a methyl-CpG binding domain-based protein to discover differentially methylated regions in cancer. [Epigenetics]

Molecular Decoy to the Y-Box Binding Protein-1 Suppresses the Growth of Breast and Prostate Cancer Cells whilst Sparing Normal Cell Viability
The data collectively suggest that the cell permeable peptide (CPP) is a novel approach to suppressing the growth of cancer cells while sparing normal cells and thereby establishes a proof-of-concept that blocking Y-box binding protein-1 activation is a new course of cancer therapeutics. [PLoS ONE]

Hypoxia-Selective Growth Inhibition of Cancer Cells by Furospinosulin-1, a Furanosesterterpene Isolated from an Indonesian Marine Sponge
Furospinosulin-1, a marine-sponge-derived furanosesterterpene, exhibited selective antiproliferative activity against DU145 human prostate cancer cells under hypoxic conditions in concentrations ranging from 1 to 100 micromolar. [ChemMedChem]

Prostate Specific Antigen Concentration at Age 60 and Death or Metastasis from Prostate Cancer: Case-Control Study
The objective of this study was to determine the relation between concentrations of prostate specific antigen at age 60 and subsequent diagnosis of clinically relevant prostate cancer in an unscreened population to evaluate whether screening for prostate cancer and chemoprevention could be stratified by risk. [Br Med J]

Balancing the Harms and Benefits of Early Detection of Prostate Cancer
For men with a low serum prostate-specific antigen level, the benefits of aggressive investigation and treatment may be limited because they are associated with a large increase in cumulative incidence and potential overtreatment. [Cancer]

Serum miRNA-21: Elevated Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer and Potential Predictive Factor for the Efficacy of Docetaxel-Based Chemotherapy
miR-21 has been recognized as an “onco-microRNA” with the activity of negatively modulating the expression of tumor-suppressor genes. However, its role in prostate cancer (CaP) has not been well-documented. Researchers designed this study to assess the potential function of serum miR-21 in the progression of CaP. [Prostate]



INDUSTRY NEWS

Maryland Stem Cell Research Commission to Host Third Annual Maryland Stem Cell Research Symposium
The Maryland Stem Cell Research Commission will host the Third Annual Maryland Stem Cell Research Symposium in partnership with the National Institutes of Health and the National Institute of Standards and Technology on Sept. 22, 2010. [The Maryland Stem Cell Research Commission Press Release]

The Karmanos Cancer Center One of the First in Michigan to use PROVENGE, the New FDA-Approved Drug for Advanced Prostate Cancer
The Barbara Ann Karmanos Cancer Center in Detroit was recently selected to be one of 50 sites in the United States to offer the new U.S. Food and Drug Administration (FDA)-approved drug PROVENGE® (sipuleucel-T) to treat patients with advanced metastatic prostate cancer. [Barbara Ann Karmanos Cancer Center Press Release]

GTx Announces That GTx-758, a Novel Oral Selective Estrogen Receptor Alpha Agonist Being Developed to Treat Advanced Prostate Cancer, Induced Medical Castration in a Phase II PK/PD Clinical Trial
GTx, Inc. announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers. [GTx, Inc. Press Release]





EVENTS (Listed by Date)

2010 Prostate Cancer Canada (PCCN) Conference
September 22-25, 2010
Toronto, Canada


International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations
September 27-28, 2010
San Francisco, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

NEW American Association for Cancer Research (AACR) Translational Cancer Research for Basic Scientists
October 17-22, 2010
Boston, United States

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

NEW Ninth Annual American Association for Cancer Research (AACR) International Conference on Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

Cancer Pharmacogenetics: Personalising Medicine
November 22-24, 2010
Madrid, Spain

NEW The 10th Annual Meeting of the Society Of Urologic Oncology (SUO) – 10th Annual Winter Meeting
December 3-5, 2010
Bethesda, United States

NEW American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

IMPaCT: Innovative Minds in Prostate Cancer Today 2011
March 9-12, 2011
Orlando, United States

NEW American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

NEW American Association for Cancer Research (AACR) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News.
Visit here to post your career opportunities.


Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us